Nafamostat

PreclinicalSmall molecule

SSeoul National University Hospital

Nafamostat is one of 12 small molecule programs targeting Anticoagulation. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

AnticoagulationRecruiting

AnticoagulationPreclinical

Recruiting

Competition

Competitive Landscape

12 competitors in Anticoagulation

#DrugCompanyPhaseTrials

Eliquis

Bristol-Myers Squibb

Approved

4 2

Xarelto

WWim Janssens

Approved

9 3

Savaysa

Daiichi Sankyo

Phase 3

4 4

Direct Anticoagulant

Bayer

Phase 3

1 5

Prismocitrate 18

VVantive Health LLC

Phase 3

1 6

Pradaxa

Boehringer Ingelheim

Preclinical

1 7

Coumadin

AAbbott

Preclinical

1 8

Antibiotic

Pfizer

Preclinical

1 9

Anticoagulation Agents

IInari Medical

Preclinical

1 10

Acenocoumarol

Roche

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2027

PreclinicalRecruiting

ECMO

NCT06676085

Clinical

Trials by Indication[1]

Postreperfusion Syndrome1 trial

Effect of Nafamostat on Postreperfusion Syndrome (PRS)

Completed·SSeoul National University Hospital·Phase 4·NCT01001403·62 enrolled

ECMO1 trial

A Novel Strategy Combined Regional Anticoagulation in Membrane Oxygenator and Low-intensity of Systemic Anticoagulation Applied in Management of Extracorporeal Membrane Oxygenation

Recruiting·BBeijing Chao Yang Hospital·Preclinical·NCT06676085·140 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for Nafamostat. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Nafamostat compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Nafamostat. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Seoul National University Hospital company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: SSeoul National University Hospital

Nafamostat

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2027

Trials by Indication[1]

Postreperfusion Syndrome1 trial

ECMO1 trial

References

Drug Info

Quick Facts

Related News